ReviewCancer treatment and research2026
Metabolic Cross Talk in the Tumor Microenvironment.
Review in Cancer treatment and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment (TME) is a dynamic network of diverse cellular and noncellular components that interact with malignant cells to influence cancer progression, immune evasion, metastasis, and the development of therapeutic resistance. The major constituents of the TME include malignant cells, immune cells, stromal cells, endothelial cells (ECs), pericytes, adipocytes, nerve cells, and the extracellular matrix (ECM). Findings revealed that a dynamic metabolic crosstalk occurs continuously within the tumor niche, leading to metabolic rewiring in the tumor resident cells that supports cancer progression under nutrient deprivation, hypoxia, and acidosis conditions in TME. This chapter provides a comprehensive overview of various types of metabolic interactions between malignant cells and the diverse cellular components of the TME, including autocrine, paracrine, juxtacrine, and endocrine-like communication, and highlights the role of key metabolites involved in this type of communication. Thus, the interplay between malignant and tumor-resident cells emphasizes their metabolic interactions that promote drug resistance. Additionally, the chapter explores the molecular mechanisms and signaling pathways triggered by this exchange of metabolites. The chapter also explores the molecular mechanisms and signaling pathways triggered by metabolite exchange and clarifies how dysregulated metabolic reprogramming contributes to cancer progression and drug resistance. Therefore, understanding these complex metabolic interactions within the tumor niche provides critical insights for developing novel therapeutic approaches that target the metabolic vulnerabilities of the malignant cells.
Indexed as
Identifiers
42144523What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.